SecBot SecBot
SECBOTREPLAY Home › Report › PHAT

PHAT · Phathom reported Q2 2026 net revenue of $74.3M, up 88% YoY and above…

Phathom Pharmaceuticals · PRESS-RELEASE filed Jul 30, 2026 at 06:59 ET

At the news

BEARISHIMPACT 6/10

PRESS-RELEASE filed Jul 30, 2026 at 06:59 ET

Phathom reported Q2 2026 net revenue of $74.3M, up 88% YoY and above the $72.7M consensus, driven by strong VOQUEZNA prescription growth. However, GAAP EPS was -$0.21, below the consensus estimate of -$0.15, and the company lowered its full-year 2026 revenue guidance to $310-325M from $320-345M, signaling a more cautious outlook despite the strong quarter. The stock is likely to trade down on the guidance cut and EPS miss, partially offset by the revenue beat and progress toward profitability.

  • Q2 2026 net revenue of $74.3M, up 88% YoY and 27% QoQ, beating consensus of $72.7M.
  • GAAP EPS of -$0.21 missed consensus of -$0.15, a 40% miss.
  • Full-year 2026 revenue guidance lowered to $310-325M from $320-345M.
  • Non-GAAP adjusted net loss was just $0.1M, nearing operating profitability.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access